Lyra Therapeutics LYRA Income Statement (2019-2025)

LYRA
$0.00 -0.04 (-100.00%)
At close: Aug 19, 2026 · 4:00 PM EDT
Income Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Shares Outstanding (Entity) (Quarter)
0.26M0.26M0.26M0.26M0.26M0.64M0.64M0.64M0.64M0.99M0.99M1.14M1.22M1.31M1.31M1.31M1.32M1.35M1.64M1.77M
Revenue & cost
Revenue (Quarter)
0.01M0.27M0.47M0.53M0.36M0.01M0.41M0.46M0.54M0.15M0.53M0.60M0.20M0.21M0.18M0.18M0.03M0.01M
Operating items
Research & Development (Quarter)
4.77M7.50M7.08M10.34M8.51M10.79M10.05M9.45M12.60M10.80M12.37M12.27M18.24M13.26M5.90M6.36M4.88M5.11M4.05M4.38M
Selling, General & Administrative (Quarter)
3.06M3.56M4.02M3.57M3.89M4.13M5.14M4.40M5.13M4.57M5.00M4.36M5.82M5.14M3.93M3.61M3.26M3.50M2.24M2.54M
Restructuring Costs (Quarter)
6.45M2.80M1.64M0.90M0.40M-0.02M0.24M
Other Operating Expenses (Quarter)
1.32M1.59M24.72M-0.01M-0.00M-0.03M
Operating Expenses (Quarter)
7.83M11.06M11.10M13.91M12.39M14.93M15.19M15.17M17.72M16.96M17.37M16.62M24.06M49.57M12.64M11.62M9.02M9.01M6.26M7.12M
Operating Income (Quarter)
-7.83M-11.06M-11.08M-13.64M-11.93M-14.40M-14.83M-15.15M-17.31M-16.50M-16.83M-16.48M-23.52M-48.97M-12.44M-11.41M-8.84M-8.83M-6.24M-7.12M
EBIT (Quarter)
-7.83M-11.06M-11.08M-13.64M-11.93M-14.40M-14.83M-15.15M-17.31M-16.50M-16.83M-16.48M-23.52M-48.97M-12.44M-11.41M-8.84M-8.83M-6.24M-7.12M
Non-operating items
Interest & Investment Income (Quarter)
0.03M0.03M0.03M0.02M0.01M0.03M0.06M-0.10M1.07M0.90M0.02M-3.14M-0.01M-0.03M0.58M0.43M0.30M1.13M
Non Operating Income (Quarter)
0.03M0.03M0.03M0.02M0.01M0.03M0.06M0.93M1.07M0.90M1.19M1.34M1.09M0.85M0.58M0.43M0.30M1.39M0.26M0.17M
Net income details
EBT (Quarter)
-13.34M-14.02M-14.80M-13.69M-11.91M-14.37M-14.77M-14.22M-16.24M-15.61M-15.63M-15.14M-22.44M-48.12M-11.87M-10.97M-8.54M-7.43M-5.98M-6.95M
Tax Provisions (Quarter)
0.01M0.01M0.02M0.02M0.01M0.01M0.01M-19.65M0.00M0.00M0.00M-6.08M
Profit After Tax (Quarter)
-7.80M-11.04M-11.05M-13.61M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.85M-10.97M-8.55M-7.44M-5.98M-6.95M
Income from Continuing Operations (Quarter)
-13.34M-14.02M-14.80M-13.69M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.87M8.67M-8.55M-7.44M-5.98M-0.87M
Consolidated Net Income (Quarter)
-13.34M-14.02M-14.80M-13.69M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.87M8.67M-8.55M-7.44M-5.98M-0.87M
Income towards Parent Company (Quarter)
-13.34M-14.02M-14.80M-13.69M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.87M8.67M-8.55M-7.44M-5.98M-0.87M
Net Income towards Common Stockholders (Quarter)
-13.34M-14.02M-14.80M-13.69M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.87M8.67M-8.55M-7.44M-5.98M-0.87M
Additional items
EPS (Basic) (Quarter)
-51.53-53.95-56.90-52.71-45.78-21.16-20.05-23.52-22.07-17.88-13.74-15.22-17.54-36.76-9.076.66-6.50-5.51-3.38-0.56
EPS (Diluted) (Quarter)
-51.53-53.95-56.90-52.71-45.78-21.16-20.05-23.52-22.07-17.88-13.74-15.22-17.54-36.76-9.076.66-6.50-5.51-3.38-0.56
Shares Outstanding (Quarter)
0.26M0.26M0.26M0.26M0.26M0.68M0.74M0.60M0.74M0.87M1.14M1.00M1.28M1.31M1.31M1.30M1.32M1.35M1.77M1.55M
Shares Outstanding (Diluted) (Quarter)
0.26M0.26M0.26M0.26M0.26M0.68M0.74M0.60M0.74M0.87M1.14M1.00M1.28M1.31M1.31M1.30M1.32M1.35M1.77M1.55M
EBITDA (Quarter)
-7.83M-11.06M-11.08M-13.64M-11.93M-14.40M-14.83M-15.15M-17.31M-16.50M-16.83M-16.48M-23.52M-48.97M-12.44M-11.41M-8.84M-8.83M-6.24M-7.12M
Interest Expenses (Quarter)
5.54M2.98M3.74M0.07M1.24M3.54M1.92M40.51M0.06M3.09M2.65M6.33M12.87M5.13M44.45M8.00M7.49M38.38M4.51M
Tax Rate (Quarter)
-0.09-0.08-0.10-0.11-0.06-0.02-0.06179.05-0.05-0.03-0.0587.48